Skip to main content
SpringerLink
Log in

Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”

  • Letter to the Editor
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. de la Fouchardière C. Comment on “Regorafenib: start low and go slow”. Target Oncol 2015. doi:10.1007/s11523-015-0407-4

  2. Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10:445–7

  3. Grothey A (2015) Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clin Adv Hematol Oncol 13(8):514–7

    PubMed  Google Scholar 

  4. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–12

    Article  CAS  PubMed  Google Scholar 

  5. Li J, Qin S, Yau T, Ma B, Pan J, Xu Y et al. (2014) CONCUR: a randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treatment metastatic colorectal cancer (mCRC) [abstract no. O-0023] Ann Oncol 25(suppl 2):ii114–ii115

  6. Tougeron D, de la Fouchardière C, Etienne PL, Dourthe LM, Mineur L, Paule B, Hollebecque A, Tresch E, Spaeth D, Michel P, Dauba J, Laplaige P, Borg C, Bechade D, Clisant S, Phelip JM, Desseigne F, Andre T, Adenis A (2014) REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC) [abstract no. 602P] Ann Oncol 25(suppl 4):iv205–iv206

  7. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667

    Article  CAS  PubMed  Google Scholar 

  8. Hofheinz R-D, Arnold D, Kubicka S, Prasnikar N, Vogel A (2015) Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat 38(6):300–8

    Article  CAS  PubMed  Google Scholar 

  9. ClinicalTrials.gov. Regorafenib in metastatic colorectal cancer. https://clinical-trials.gov/ct2/show/NCT02466009. ID: NCT02466009.

  10. Ducreux MP, Falcone A, Punt CJA, Thaler J, Poehlein CH, Cervantes A (2014) A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (MCRC) in routine clinical practice (CORRELATE) [abstract no. 613TiP]. Ann Oncol. 25(suppl 4):iv209

  11. Sargent DJ, Köhne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27(12):1948–55

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Hematology Oncology Department, Saint Joseph University, Beirut, Lebanon

    Samer Tabchi & Marwan Ghosn

Authors
  1. Samer Tabchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwan Ghosn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samer Tabchi.

Ethics declarations

Funding

None

Conflict of Interest

Samer Tabchi and Marwan Ghosn declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tabchi, S., Ghosn, M. Author’s Reply to Christelle de la Fouchardière: “Regorafenib: Start Low and Go Slow”. Targ Oncol 11, 127–128 (2016). https://doi.org/10.1007/s11523-015-0406-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-015-0406-5

Keywords

Search

Navigation